Gyre Therapeutics reported Q3 2025 net income of $5.9 million, with quarterly revenue of $30.6 million, up 20% year-over-year. The company revised full-year revenue guidance to $115-118 million due to delayed product rollouts and procurement uncertainties.

Gyre Therapeutics will present positive Phase 3 clinical trial results for Hydronidone, a novel anti-fibrotic agent targeting liver fibrosis in chronic hepatitis B, at AASLD's The Liver Meeting® 2025 in Washington D.C.

Gyre Therapeutics announced the appointment of Dr. Dan Weng to its Board of Directors, bringing nearly four decades of clinical trial management experience. The company is focused on developing fibrosis treatments and has a prominent product in the Chinese market.

Gyre Therapeutics announced the first dosing in a Phase 1 clinical trial of its novel drug F230 for the treatment of pulmonary arterial hypertension (PAH) in China. This milestone marks Gyre's entry into the PAH field, a rare and high-mortality condition with limited treatment options.

Gyre Therapeutics, a biotechnology company, announced the pricing of its public offering of 2,222,222 shares of common stock at $9.00 per share, with an option for underwriters to purchase an additional 333,333 shares. The company plans to use the net proceeds to advance its clinical trial and for general corporate purposes.

Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology

Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes

Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results. Fastenal reported first-quarter FY24 sales growth of 1.9% Y/Y to $1.895 billion, missing the consensus of $1.914 billion. The company's first-quarter EPS was 52 cents, missing the consensus of 53 cents. Fastenal shares dipped 6.7% to $69.73 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Rallybio Corporation (NASDAQ: RLYB) shares climbed 89.6% to $3.09 after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant individuals at risk of FNAIT. Rent the Runway, Inc. (NASDAQ: RENT) shares jumped 74.5% to $12.91 after the company reported mixed fourth-quarter financial results and issued guidance. Eliem Therapeutics, Inc. (NASDAQ: ELYM) jumped 59.6% to $4.2650. The company announced that it entered into a definitive acquisition agreement to acquire Tenet and it also entered into a securities purchase agreement for a $120 million private placement. Akanda Corp. (NASDAQ: AKAN) gained 36% to $0.1632. Akanda, last month, announced a plan to evaluate opportunities in Bitcoin, Blockchain and AI applications in the cannabis industry. Alpine Immune Sciences, Inc. (NASDAQ: ALPN) rose 36.6% to $64.25 after Vertex entered into an agreement to acquire the company. Candel Therapeutics, Inc. (NASDAQ: CADL) surged 29.6% to $6.61 after the company received FDA orphan drug designation for CAN-2409 for the treatment of pancreatic cancer. Enliven Therapeutics, Inc. (NASDAQ: ELVN) gained 26% to $24.97. Enliven Therapeutics announced proof ...

U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose sharply during Thursday’s session. Enliven Therapeutics announced proof of concept data from Phase 1 clinical trial of ELVN-001 in chronic myeloid leukemia. Enliven Therapeutics shares surged 26% to $24.97 on Thursday. Here are some other big stocks recording losses in today’s session. Rallybio Corporation (NASDAQ: RLYB) shares gained 89.6% to $3.09 after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant individuals at risk of FNAIT. Alpine Immune Sciences, ...

Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum